AstraZeneca (AZN) Seeks FDA Approval for New Lung Cancer Treatment. Can It Fuel Oncology Growth?

What happened: AstraZeneca PLC (NYSE:AZN) applied to the US FDA for approval of ORPATHYS-TAGRISSO, a lung cancer combination developed with HUTCHMED, Reuters reported on September 29. Key numbers: AZN shares lost about 14% year to date. Why it matters: Approval would extend Tagrisso to patients whose cancers develop MET-driven resistance after EGFR-targeted therapy, and the combination is already approved in China, so US clearance could widen its geographic reach. The FDA review and a narrower target population remain risks. Market: +0.3% by next close ($159.20 on Oct 9), -10.6% YTD

AstraZeneca PLC (NYSE:AZN) applied to the US FDA for approval of ORPATHYS-TAGRISSO, a lung cancer combination developed with HUTCHMED, Reuters reported on September 29.

Approval would extend Tagrisso to patients whose cancers develop MET-driven resistance after EGFR-targeted therapy, and the combination is already approved in China, so US clearance could widen its geographic reach. The FDA review and a narrower target population remain risks. Market: +0.3% by next close ($159.20 on Oct 9), -10.6% YTD